Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Company’s pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.
CUV - Clinuvel Pharmaceuticals Ltd
Report
There was a problem reporting this post.
Block Member?
Please confirm you want to block this member.
You will no longer be able to:
See blocked member's posts
Mention this member in posts
Please allow a few minutes for this process to complete.